论文部分内容阅读
目的观察卡维地洛及美托洛尔在治疗慢性心力衰竭患者中的临床疗效。方法将79例慢性心力衰竭患者随机分为卡维地洛组(28例),美托洛尔组(26例)及对照组(25例),均予常规抗心衰治疗,卡维地洛组在常规治疗基础上加用卡维地洛口服,美托洛尔组加用美托洛尔口服,随访半年,心功能改善二级以上为显效,改善一级为有效,无改善并恶化为无效。结果卡维地洛组有效率93%,美托洛尔组有效率92%,对照组总有效率为72%,卡维地洛及美托洛尔组均与对照组有显著差异,但二者之间无显著差异。结论β受体阻滞剂可改善心衰预后,卡维地洛及美托洛尔疗效未见差异。
Objective To observe the clinical efficacy of carvedilol and metoprolol in the treatment of patients with chronic heart failure. Methods 79 patients with chronic heart failure were randomly divided into carvedilol group (28 cases), metoprolol group (26 case) and control group (25 cases). All patients were given conventional anti-heart failure treatment and carvedilol The group was treated with carvedilol orally on the basis of conventional treatment. The metoprolol group was treated with metoprolol orally. After six months of follow-up, heart function improved more than the second grade was markedly effective, the first grade was effective, no improvement and worsened to invalid. Results The effective rate was 93% in the carvedilol group, 92% in the metoprolol group, and 72% in the control group. There was significant difference between the carvedilol group and the metoprolol group and the control group No significant difference between. Conclusion β-blockers can improve the prognosis of heart failure, carvedilol and metoprolol no difference.